AstraZeneca Pharma India Ltd
Thu 13/03/2025,15:54:48 | NSE : ASTRAZEN
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 7710.00
Previous Close
₹ 7706.85
Volume
59650
Mkt Cap ( Rs. Cr)
₹19188.88
High
₹ 7970.60
Low
₹ 7584.00
52 Week High
₹ 8139.00
52 Week Low
₹ 4785.00
Book Value Per Share
₹ 271.74
Dividend Yield
0.31
Face Value
₹ 2.00
What’s Your Call?
Collective community sentiment on AstraZeneca Pharma India Ltd
Your Vote -
Buy
64.58%
Hold
5.21%
Sell
30.21%
64.58%
96 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
0%
Sell Order Quantity
100%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
7675.55
113
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
113
Option Chain
Analyzes market sentiment, predicts AstraZeneca Pharma India Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
AstraZeneca Pharma I - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2
-
AstraZeneca Pharma I - Updates
-
AstraZeneca Pharma I - Updates
-
AstraZeneca Pharma I - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements)\r\nRegulation
-
AstraZeneca Pharma I - Integrated Filing (Financial)
-
AstraZeneca Pharma I - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2
-
AstraZeneca Pharma I - Updates
-
AstraZeneca Pharma I - Copy of Newspaper Publication
-
AstraZeneca Pharma I - Notice Of Shareholders Meetings-XBRL
-
AstraZeneca Pharma I - Updates
-
AstraZeneca Pharma I - Shareholders meeting
-
AstraZeneca Pharma I - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
-
AstraZeneca Pharma I - Integrated Filing- Financial
-
AstraZeneca Pharma I - Copy of Newspaper Publication
-
AstraZeneca Pharma I Q3 net profit jumps 95.25% at Rs 30.85 cr
-
AstraZeneca Pharma I - Outcome Of The Board Meeting Held On Tuesday, February 11, 2025
-
AstraZeneca Pharma I - Financial Result Updates
-
AstraZeneca Pharma I - Press Release
-
AstraZeneca Pharma I - Press Release
-
AstraZeneca Pharma I - Board Meeting Outcome for Outcome Of The Board Meeting Held On Tuesday, February 11, 2025
-
AstraZeneca Pharma I - Outcome of Board Meeting
-
AstraZeneca Pharma I - General Updates
-
AstraZeneca Pharma I - General Updates
-
AstraZeneca Pharma I - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
AstraZeneca Pharma I - Updates
-
AstraZeneca Pharma I - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
AstraZeneca Pharma I - General Updates
-
AstraZeneca Pharma I - Board Meeting Intimation
-
AstraZeneca Pharma I - Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Tuesday, F
-
AstraZeneca Pharma I has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2024
-
AstraZeneca Pharma I - General Updates
-
AstraZeneca Pharma I - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2
-
AstraZeneca Pharma I - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
AstraZeneca Pharma I - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
AstraZeneca Pharma I - Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
-
AstraZeneca Pharma I - Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
-
AstraZeneca Pharma I - Shareholders meeting
-
Astrazenaca Pharma
-
AstraZeneca Pharma
-
Astrazenaca Pharma
-
Astrazeneca Pharma Trade
-
AstraZeneca Pharma rises as co gets CDSCO nod
-
AstraZenecea Pharma India
-
Astrazenca Pharma India
-
Astrazeneca Pharma
-
AstraZeneca Pharma
-
AstraZeneca Pharma India
-
Astrazenca Pharma India Ltd
-
Asterzenca Pharma
-
Astrazeneca Pharma receives Import and Market Permission in Form CT-20
-
AstraZeneca Pharma gets import and market permission for Benralizumab
-
AztraZeneca to launch oncology drug Calquence in India
-
AstraZeneca Pharma hits fresh record high
-
AstraZeneca gets import and market permission for Olaparib Film-Coated tablets
-
Astrazeneca Pharma India
-
AstraZeneca gets DCGI approval for type 2 diabetes drug
-
AstraZeneca gets DGCI nod for cancer drug
-
Astrazeneca to invest $90 mn over next 5 years in India
-
AstraZeneca gets nod for importing diabetes drug
Key fundamentals
Evaluate the intrinsic value of AstraZeneca Pharma India Ltd stock
Name | March-24 | March-23 | March-22 | March-21 | March-20 |
---|---|---|---|---|---|
Assets | 711.92 | 588.69 | 511.39 | 456.17 | 364.44 |
Liabilities | 711.92 | 588.69 | 511.39 | 456.17 | 364.44 |
Equity | 5 | 5 | 5 | 5 | 5 |
Gross Profit | 184.45 | 165.12 | 86.18 | 135.47 | 120.7 |
Net Profit | 161.51 | 99.29 | 61.6 | 93.3 | 72.21 |
Cash From Operating Activities | 27.87 | 58.29 | 100.8 | 104.78 | 87.42 |
NPM(%) | 12.46 | 9.89 | 7.64 | 11.46 | 8.68 |
Revenue | 1295.53 | 1002.97 | 805.6 | 813.56 | 831.81 |
Expenses | 1111.08 | 837.85 | 719.42 | 678.09 | 711.11 |
ROE(%) | 23.77 | 14.61 | 9.06 | 13.73 | 10.62 |
Corporate Action
XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
---|---|---|---|---|
05 Jul 2024 | 24 | 1200 | 0.31 | 6432.8 |
07 Jul 2022 | 8 | 400 | 0.31 | 2639.1 |
18 Aug 2021 | 2 | 100 | 0.31 | 3364.65 |
20 Aug 2020 | 2 | 100 | 0.31 | 3379.3 |
20 Aug 2019 | 1 | 50 | 0.31 | 1956.35 |
07 Jul 2011 | 10 | 500 | 0.31 | 1319.85 |
06 May 2010 | 10 | 500 | 0.31 | 881.45 |
29 Apr 2009 | 15 | 750 | 0.31 | 485.6 |
11 Apr 2008 | 15 | 750 | 0.31 | 547.9 |
22 Mar 2007 | 12 | 600 | 0.31 | 595 |
60 | 600 | 0.31 | 610.25 | |
12 Apr 2006 | 20 | 200 | 0.31 | 3131.3 |
18 Mar 2005 | 50 | 500 | 0.31 | 1594.2 |
16 Apr 2004 | 3.9 | 39 | 0.31 | 1089.15 |
15 May 2002 | 0 | 30 | 0.31 | 362.45 |
18 Jun 2001 | 0 | 40 | 0.31 | 429.85 |
11 Aug 2000 | 0 | 5 | 0.31 | 294.3 |
0 | 35 | 0.31 | 205 | |
0 | 33 | 0.31 | 272.1 |
Peers
Other companies within the same industry or sector that are comparable to AstraZeneca Pharma India Ltd
Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
---|---|---|---|---|---|---|
Albert David Ltd | 808.20 | -1.14 | 11.41 | 4371.89 | 1321.50 | 1.42 |
Lotus Eye Hospital and Institute Ltd | 57.06 | -0.77 | 237.75 | 15930.59 | 14.01 | 0.88 |
Vaishali Pharma Ltd | 12.12 | -5.90 | 606.00 | 8211.24 | 2.31 | 0.00 |
Astec Lifesciences Ltd | 653.90 | -5.55 | 0.00 | 15021.17 | -239.30 | 0.00 |
Company Info
YEAR EVENTS 1979 - The Company was incorporated on 11th July, and the Certificate of Commencement of Business was obtained on 6th November, 1979. It was promoter jointly by Astra Pharmaceuticals AB, Sweden (Astra) and IDL Chemicals Ltd., Hyderabad (IDL). 1980 - The Company entered into a technical collaboration with Astra Pharmaceuticals AB, Sweden for the supply for information and know-how and all manufacturing process and technical data for the manufacture of basic drugs, formulations, fine chemicals and industrial chemicals. - The Company undertook to set up a project at Yelahanka, Bangalore, for the manufacture of basic drugs, formulations, fine and industrial chemicals. Pharmaceuticals and chemicals plant was commissioned in February 1982. 1982 - 2,000 shares issued to promoters, etc. 24,98,000 shares issued at par; 6,43,235 shares each allotted to Astra Pharmaceuticals AB, Sweden and IDL Chemicals, Ltd.; 3,78,830 shares allotted to Indian directors, shareholders and employees, shareholders and employees, etc. of the company and also that of IDL Chemicals, Ltd. and 8,32,700 shares offered for public subscription during February-March, 1982. 1988 - The Company launched `SENSORCAINE', a long acting local anaesthetic for use in surgical anaesthesia and introduced `THEOBRIC', a combination branco dilator for asthma. The Company also planned to launch new products based on original research of Astra in the fields of peptic ulcer, hypertension and asthma. - The Company launched during the year `RESTOMYCIN', an antibiotic `BROMENYL', a cough expectorant and `FEBRAFEN' a pain and fever reliever. - The company was also in the process of creating in-house facilities for the manufacture of products based on inhalation therapy and formulation therapy and formulations based on prostaglandins. - The Company launched `PROSTODIN', the first protagladin with an important indication for postpartum haemorage, etc. Several new products were launched during the year, namely, SELOPRES, BETALOC DURULES, TRIPRES, SENSORCAINE SPINAL and BRICANYL NEBULISING SOLUTION. It also launched products based on inhalation therapy such as `PULMICORTINHALER' BRICANYL INHALER and SPACEHALER. 1991 - The Company launched a product in the Prostaglandins range `PIMIPROST' for the promotion of safe motherhood. 1992 - The Company launched Prostaglandin `Cerviprime Gel' for preinduction cervical ripening and `Plendil' a new generation calcium antagonist. The Company proposed to launch `Ramace', `Rhinocort' and `Imdur'. 1994 - Several new products were launched during the year, namely, Ramace and Imdur, which strengthen the cardiovascular range of products. Similarly Rhinocort was introduced which is in the range of respiratory care products. 1995 - 25,00,000 bonus shares issued in prop. 1:1. 1996 - Two new line of extension namely `Jumbo' pack of Pulmicort & Bricanyl Inhalers 400 metered doses were introduced in the respiratory group. A low dose aspirin formation to correct thromboembolic disorders was launched. Also Imdur 30 mg to support Imdur 60 mg was introduced. 1997 - A range of new products viz., Xylocaine Spray in pain control segment, Stop-it in Anti-infective segment, Mimbid in NSAID segment, Linctus-D and Rhinocort Aqua in Respiratory segment, Rejois in Maternal health care segment and Cellubril, a stool softner. - The company established state-of-the-art production facilities for aerosols and soft gelatin capsules near its formulations plant. - A joint venture between Astra AB of Sweden and IDL Industries of the Hindujas, Astra-IDL has been the subject of a prolonged litigation between the two promoters. - A joint venture between the US $ 7-billion Swedish pharmaceutical major Astra AB and IDL Industries of the Hindujas. 1998 - Wipro, Honda Siel Power Products, and Astra-IDL have been conferred the Analyst Awards, by The Institute of Chartered Financial Analysts of India (ICFAI). - Astra had set up a 100 per cent research facility in Bangalore three years ago. 1999 - Even as the Hindujas continue to seek new alignments to replace multinational AstraZeneca in their joint venture Astra-IDL Ltd. 2000 - UB's 100 per cent subsidiary, UB Bioteck, has tied up with Astra IDL Ltd to market its newly-patented anti-obesity nutraceutical. - Mr. D.E. Udwadia, Director, has been appointed as the Chairman. 2001 - Crisil has placed the `FAA' rating on the fixed deposit programme of the company on a `rating watch with positive implications'. - The Company upon the acquisition, Astra, Swden now holds 51.50 per cent of the company's issued and paid-up equity shares capital. The company is therefore a subsidiary of Astra, Swden and has become a part of the worldwide AstraZeneca Group. - The Managing Director, Mr. A.R. Hegde, has resigned from the company. - Astra-IDL Ltd will be renamed AstraZeneca Pharma India Ltd and Mr Lars Walan, recently designated Managing director, will take over on April 2 from Mr. A.R. Hegde, MD, who has resigned. 2002 -Ties up with Avestha for research on discovering drug for tuberculosis. -Makes an open offer to acquire the balance 21,75,050 equity shares of Astrazeneca pharma India Ltd representing 43% stake. -Government okays FDI proposal for the company and Tata Homefinance from 56.69% to 100% accounting for Rs.82 crs. -Astra Pharma acquires 32800 equity shares of Astrazeneca. 2003 -Astra Pharma and Astrazeneca jointly acquires less than 4% additional equity Astrazeneca Pharma India Ltd. -Sri Tom McKillop, inaugurates R & D centre in Bangalore at a cost of $40 million. -Approaches Union government for Exclusive Marketing Rights for new two generation anti-cancer drugs. -Astrazeneca Pharma India Limited Board accepts resignation of Mr. J G Zetterberg, Director, effective from the close of May 05, 2004. 2006 -AstraZeneca acquires Eli Lilly's Vancocin brand -Company has splits its Face value of Shares from Rs 10 to Rs 2 2007 -AstraZeneca Pharma India Ltd has appointed Mr. Ruud Dobber as Director of the Company. 2010 - AstraZeneca Pharma and biopharmaceutical company Bristol-Myers Squibb launched their 9-month-old diabetes drug Onglyza in India - the biggest market for the drug.Onglyza, or saxagliptin, is used to treat type 2 diabetes in adults. - AstraZeneca Pharma India Ltd has appointed Ms. Anita Zutshi as the Chief Financial Officer of the Company. 2011 -AstraZeneca Halts Late-Stage Trial of Prostate Cancer Medicine Zibotentan -Appointment of Mr. Himanshu Agarwal as the CFO of the Company 2012 -AstraZeneca Excellence in Chemistry Awards 2011 -AstraZeneca and Cellworks Collaborate to find new Treatment for Tuberculosis -AstraZeneca launches its patented life-saving heart drug BRILINTAr (Ticagrelor) in India 2013 -AstraZeneca to acquire Bristol-Myers Squibb share of global diabetes alliance assets -AstraZeneca enters co-promotion agreement with Janssen in Japan for innovative prostate cancer treatment. 2014 -AstraZeneca and Bristol-Myers Squibb Company today announced the US Food and Drug Administration (FDA) approved FARXIGAT (dapagliflozin). -AstraZeneca and MRC enter strategic collaboration to create new centre for early drug discovery in Cambridge, UK . -AstraZeneca and Roche announce partnership to develop companion diagnostic test for AZD9291 -The Registered Office of the Company has been shifted from 'Avishkar', Off Bellary Road, Hebbal, Bangalore - 560 024 to Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore - 560 045. 2015 -AstraZeneca Pharma India Limited and Dr Reddy's Laboratories Limited enter distribution agreement for saxagliptin and its fixed dose combination with metformin, in Type 2 Diabetes -AstraZeneca Pharma launches type-2 diabetes treatment drug -BRILIQUE (ticagrelor) receives positive European Union CHMP opinion for extended treatment of patients with a history of heart attack -AstraZeneca completes acquisition of ZS Pharma -AstraZeneca opens new manufacturing facility to support continued growth in Russia 2017 -AstraZeneca Pharma receives import permission for inhaler powder. -AstraZeneca Pharma receives approval for Osimertinib Tablet. 2018 -AZPIL receives permission for Durvalumab from Drug Controller General of India. 2021 -AstraZeneca's Partners With DocOn to Digitise Healthcare Clinics Across India. -AstraZeneca in collaboration with Rajiv Gandhi Cancer Institute announces the launch of Project Chariot to help diagnose and treat patients with Chronic Lymphocytic Leukemia (CLL). -AstraZeneca launches Clinical Data and Insights division in India. 2022 -AstraZeneca Pharma gets CDSCO nod for Dapagliflozin tablets. 2023 -AstraZeneca Inaugurates "Centre of Excellence" at Manipal Hospital Goa for Severe Asthma Patients. -AstraZeneca India partners with Roche Diagnostics India to improve diagnostic testing for breast cancer patients. -Govt. of Karnataka signs MoU with AstraZeneca India to accelerate Lung Cancer testing. 2024 -AstraZeneca Pharma India Ltd and Mankind Pharma Ltd announced a collaboration for the exclusive distribution of the asthma medication brand, Symbicort, in India. -AstraZeneca India receives Central Drugs Standard Control Organisation approval for Durvalumab for specified additional indication. -AstraZeneca and Vaayu Chest & Sleep Center collaborate to enhance respiratory care for severe asthma patients in Bengaluru. -AstraZeneca receives CDSCO approval to import and market Andexanet Alfa in India for critical bleeding conditions associated with use of novel anticoagulants.
YEAR EVENTS 1979 - The Company was incorporated on 11th July, and the Certificate of Commencement of Business was obtained on 6th November, 1979. It was promoter jointly by Astra Pharmaceuticals AB, Sweden (Astra) and IDL Chemicals Ltd., Hyderabad (IDL). 1980 - The Company entered into a technical collaboration with Astra Pharmaceuticals AB, Sweden for the supply for information and know-how and all manufacturing process and technical data for the manufacture of basic drugs, formulations, fine chemicals and industrial chemicals. - The Company undertook to set up a project at Yelahanka, Bangalore, for the manufacture of basic drugs, formulations, fine and industrial chemicals. Pharmaceuticals and chemicals plant was commissioned in February 1982. 1982 - 2,000 shares issued to promoters, etc. 24,98,000 shares issued at par; 6,43,235 shares each allotted to Astra Pharmaceuticals AB, Sweden and IDL Chemicals, Ltd.; 3,78,830 shares allotted to Indian directors, shareholders and employees, shareholders and employees, etc. of the company and also that of IDL Chemicals, Ltd. and 8,32,700 shares offered for public subscription during February-March, 1982. 1988 - The Company launched `SENSORCAINE', a long acting local anaesthetic for use in surgical anaesthesia and introduced `THEOBRIC', a combination branco dilator for asthma. The Company also planned to launch new products based on original research of Astra in the fields of peptic ulcer, hypertension and asthma. - The Company launched during the year `RESTOMYCIN', an antibiotic `BROMENYL', a cough expectorant and `FEBRAFEN' a pain and fever reliever. - The company was also in the process of creating in-house facilities for the manufacture of products based on inhalation therapy and formulation therapy and formulations based on prostaglandins. - The Company launched `PROSTODIN', the first protagladin with an important indication for postpartum haemorage, etc. Several new products were launched during the year, namely, SELOPRES, BETALOC DURULES, TRIPRES, SENSORCAINE SPINAL and BRICANYL NEBULISING SOLUTION. It also launched products based on inhalation therapy such as `PULMICORTINHALER' BRICANYL INHALER and SPACEHALER. 1991 - The Company launched a product in the Prostaglandins range `PIMIPROST' for the promotion of safe motherhood. 1992 - The Company launched Prostaglandin `Cerviprime Gel' for preinduction cervical ripening and `Plendil' a new generation calcium antagonist. The Company proposed to launch `Ramace', `Rhinocort' and `Imdur'. 1994 - Several new products were launched during the year, namely, Ramace and Imdur, which strengthen the cardiovascular range of products. Similarly Rhinocort was introduced which is in the range of respiratory care products. 1995 - 25,00,000 bonus shares issued in prop. 1:1. 1996 - Two new line of extension namely `Jumbo' pack of Pulmicort & Bricanyl Inhalers 400 metered doses were introduced in the respiratory group. A low dose aspirin formation to correct thromboembolic disorders was launched. Also Imdur 30 mg to support Imdur 60 mg was introduced. 1997 - A range of new products viz., Xylocaine Spray in pain control segment, Stop-it in Anti-infective segment, Mimbid in NSAID segment, Linctus-D and Rhinocort Aqua in Respiratory segment, Rejois in Maternal health care segment and Cellubril, a stool softner. - The company established state-of-the-art production facilities for aerosols and soft gelatin capsules near its formulations plant. - A joint venture between Astra AB of Sweden and IDL Industries of the Hindujas, Astra-IDL has been the subject of a prolonged litigation between the two promoters. - A joint venture between the US $ 7-billion Swedish pharmaceutical major Astra AB and IDL Industries of the Hindujas. 1998 - Wipro, Honda Siel Power Products, and Astra-IDL have been conferred the Analyst Awards, by The Institute of Chartered Financial Analysts of India (ICFAI). - Astra had set up a 100 per cent research facility in Bangalore three years ago. 1999 - Even as the Hindujas continue to seek new alignments to replace multinational AstraZeneca in their joint venture Astra-IDL Ltd. 2000 - UB's 100 per cent subsidiary, UB Bioteck, has tied up with Astra IDL Ltd to market its newly-patented anti-obesity nutraceutical. - Mr. D.E. Udwadia, Director, has been appointed as the Chairman. 2001 - Crisil has placed the `FAA' rating on the fixed deposit programme of the company on a `rating watch with positive implications'. - The Company upon the acquisition, Astra, Swden now holds 51.50 per cent of the company's issued and paid-up equity shares capital. The company is therefore a subsidiary of Astra, Swden and has become a part of the worldwide AstraZeneca Group. - The Managing Director, Mr. A.R. Hegde, has resigned from the company. - Astra-IDL Ltd will be renamed AstraZeneca Pharma India Ltd and Mr Lars Walan, recently designated Managing director, will take over on April 2 from Mr. A.R. Hegde, MD, who has resigned. 2002 -Ties up with Avestha for research on discovering drug for tuberculosis. -Makes an open offer to acquire the balance 21,75,050 equity shares of Astrazeneca pharma India Ltd representing 43% stake. -Government okays FDI proposal for the company and Tata Homefinance from 56.69% to 100% accounting for Rs.82 crs. -Astra Pharma acquires 32800 equity shares of Astrazeneca. 2003 -Astra Pharma and Astrazeneca jointly acquires less than 4% additional equity Astrazeneca Pharma India Ltd. -Sri Tom McKillop, inaugurates R & D centre in Bangalore at a cost of $40 million. -Approaches Union government for Exclusive Marketing Rights for new two generation anti-cancer drugs. -Astrazeneca Pharma India Limited Board accepts resignation of Mr. J G Zetterberg, Director, effective from the close of May 05, 2004. 2006 -AstraZeneca acquires Eli Lilly's Vancocin brand -Company has splits its Face value of Shares from Rs 10 to Rs 2 2007 -AstraZeneca Pharma India Ltd has appointed Mr. Ruud Dobber as Director of the Company. 2010 - AstraZeneca Pharma and biopharmaceutical company Bristol-Myers Squibb launched their 9-month-old diabetes drug Onglyza in India - the biggest market for the drug.Onglyza, or saxagliptin, is used to treat type 2 diabetes in adults. - AstraZeneca Pharma India Ltd has appointed Ms. Anita Zutshi as the Chief Financial Officer of the Company. 2011 -AstraZeneca Halts Late-Stage Trial of Prostate Cancer Medicine Zibotentan -Appointment of Mr. Himanshu Agarwal as the CFO of the Company 2012 -AstraZeneca Excellence in Chemistry Awards 2011 -AstraZeneca and Cellworks Collaborate to find new Treatment for Tuberculosis -AstraZeneca launches its patented life-saving heart drug BRILINTAr (Ticagrelor) in India 2013 -AstraZeneca to acquire Bristol-Myers Squibb share of global diabetes alliance assets -AstraZeneca enters co-promotion agreement with Janssen in Japan for innovative prostate cancer treatment. 2014 -AstraZeneca and Bristol-Myers Squibb Company today announced the US Food and Drug Administration (FDA) approved FARXIGAT (dapagliflozin). -AstraZeneca and MRC enter strategic collaboration to create new centre for early drug discovery in Cambridge, UK . -AstraZeneca and Roche announce partnership to develop companion diagnostic test for AZD9291 -The Registered Office of the Company has been shifted from 'Avishkar', Off Bellary Road, Hebbal, Bangalore - 560 024 to Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore - 560 045. 2015 -AstraZeneca Pharma India Limited and Dr Reddy's Laboratories Limited enter distribution agreement for saxagliptin and its fixed dose combination with metformin, in Type 2 Diabetes -AstraZeneca Pharma launches type-2 diabetes treatment drug -BRILIQUE (ticagrelor) receives positive European Union CHMP opinion for extended treatment of patients with a history of heart attack -AstraZeneca completes acquisition of ZS Pharma -AstraZeneca opens new manufacturing facility to support continued growth in Russia 2017 -AstraZeneca Pharma receives import permission for inhaler powder. -AstraZeneca Pharma receives approval for Osimertinib Tablet. 2018 -AZPIL receives permission for Durvalumab from Drug Controller General of India. 2021 -AstraZeneca's Partners With DocOn to Digitise Healthcare Clinics Across India. -AstraZeneca in collaboration with Rajiv Gandhi Cancer Institute announces the launch of Project Chariot to help diagnose and treat patients with Chronic Lymphocytic Leukemia (CLL). -AstraZeneca launches Clinical Data and Insights division in India. 2022 -AstraZeneca Pharma gets CDSCO nod for Dapagliflozin tablets. 2023 -AstraZeneca Inaugurates "Centre of Excellence" at Manipal Hospital Goa for Severe Asthma Patients. -AstraZeneca India partners with Roche Diagnostics India to improve diagnostic testing for breast cancer patients. -Govt. of Karnataka signs MoU with AstraZeneca India to accelerate Lung Cancer testing. 2024 -AstraZeneca Pharma India Ltd and Mankind Pharma Ltd announced a collaboration for the exclusive distribution of the asthma medication brand, Symbicort, in India. -AstraZeneca India receives Central Drugs Standard Control Organisation approval for Durvalumab for specified additional indication. -AstraZeneca and Vaayu Chest & Sleep Center collaborate to enhance respiratory care for severe asthma patients in Bengaluru. -AstraZeneca receives CDSCO approval to import and market Andexanet Alfa in India for critical bleeding conditions associated with use of novel anticoagulants.
Read More
Parent Organisation
AstraZeneca Pharma India Ltd.
Founded
11/07/1979
Managing Director
NSE Symbol
ASTRAZENEQ
FAQ
The current price of AstraZeneca Pharma India Ltd is ₹ 7675.55.
The 52-week high for AstraZeneca Pharma India Ltd is ₹ 7970.60 and the 52-week low is ₹ 7584.00.
The market capitalization of AstraZeneca Pharma India Ltd is currently ₹ 19188.88. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy AstraZeneca Pharma India Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in AstraZeneca Pharma India Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase AstraZeneca Pharma India Ltd shares.
The CEO of AstraZeneca Pharma India Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.